|
PL2352763T5
(pl)
*
|
2008-10-01 |
2023-01-30 |
Amgen Research (Munich) Gmbh |
Bispecyficzne przeciwciała jednołańcuchowe o specyficzności wobec antygenów docelowych o dużej masie cząsteczkowej
|
|
ES2656442T3
(es)
*
|
2011-09-19 |
2018-02-27 |
Axon Neuroscience Se |
Terapia basada en proteínas y diagnóstico de una patología mediada por tau en la enfermedad de Alzheimer
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
JP6226752B2
(ja)
|
2012-02-09 |
2017-11-08 |
中外製薬株式会社 |
抗体のＦｃ領域改変体
|
|
WO2014059442A2
(en)
*
|
2012-10-12 |
2014-04-17 |
Arizona Board Agents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University |
Antibody based reagents that specifically recognize toxic oligomeric forms of tau
|
|
CA2902026C
(en)
|
2013-03-13 |
2023-08-29 |
Prothena Biosciences Limited |
Tau immunotherapy
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
HRP20200384T1
(hr)
*
|
2013-12-20 |
2020-06-12 |
F. Hoffmann - La Roche Ag |
Humanizirana anti-tau(ps422) protutijela i načini uporabe
|
|
EP3327038B1
(en)
*
|
2013-12-20 |
2020-09-23 |
F. Hoffmann-La Roche AG |
Bispecific her2 antibodies and methods of use
|
|
RU2678810C2
(ru)
*
|
2014-02-02 |
2019-02-01 |
Медиммун Лимитед |
ХИМЕРНЫЙ БЕЛОК, СОСТАВЛЕННЫЙ ИЗ ДОМЕНА АНТАГОНИСТА NGF И ДОМЕНА АНТАГОНИСТА TNFα
|
|
KR20230104759A
(ko)
|
2014-09-30 |
2023-07-10 |
뉴리뮨 홀딩 아게 |
인간-유래의 항-디펩티드 반복체(dpr) 항체
|
|
CN110894240B
(zh)
|
2014-11-26 |
2022-04-15 |
森科股份有限公司 |
结合cd3和肿瘤抗原的异二聚体抗体
|
|
EP4465050A3
(en)
|
2015-06-05 |
2025-06-11 |
Genentech, Inc. |
Anti-tau antibodies and methods of use
|
|
US11130815B2
(en)
|
2015-06-24 |
2021-09-28 |
Jcr Pharmaceuticals Co., Ltd. |
Fusion proteins containing a BDNF and an anti-human transferrin receptor antibody
|
|
TWI769982B
(zh)
*
|
2015-06-24 |
2022-07-11 |
日商Ｊｃｒ製藥股份有限公司 |
通過血腦障壁之抗人類運鐵蛋白受體抗體
|
|
CN107810196B
(zh)
|
2015-06-24 |
2021-11-05 |
豪夫迈·罗氏有限公司 |
人源化的抗-Tau(pS422)抗体和使用方法
|
|
KR102770650B1
(ko)
|
2015-07-06 |
2025-02-19 |
유씨비 바이오파마 에스알엘 |
타우 결합 항체
|
|
CA2991264C
(en)
|
2015-07-06 |
2023-10-10 |
Ucb Biopharma Sprl |
Tau-binding antibodies
|
|
FI3334761T3
(fi)
*
|
2015-08-13 |
2023-08-14 |
Univ New York |
Vasta-ainepohjaisia molekyylejä, jotka ovat selektiivisiä Taun {p}Ser404-epitoopille, ja niiden käyttöjä tauopatian diagnosoinnissa ja hoidossa
|
|
WO2017176835A2
(en)
*
|
2016-04-06 |
2017-10-12 |
Imago Pharmaceuticals, Inc. |
Therapeutic antibodies for treatment of neurodegeneration
|
|
CA3022515A1
(en)
|
2016-05-02 |
2017-11-09 |
Prothena Biosciences Limited |
Antibodies recognizing tau
|
|
EP3452507B1
(en)
|
2016-05-02 |
2022-10-19 |
Prothena Biosciences Limited |
Tau immunotherapy
|
|
PE20190208A1
(es)
|
2016-05-02 |
2019-02-07 |
Prothena Biosciences Ltd |
Anticuerpos que reconocen tau
|
|
KR20190022632A
(ko)
|
2016-06-20 |
2019-03-06 |
에프-스타 베타 리미티드 |
Lag-3 결합 구성원
|
|
CA3030754C
(en)
*
|
2016-07-20 |
2022-04-26 |
Anahit Ghochikyan |
Humanized anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
|
|
WO2018018031A1
(en)
*
|
2016-07-22 |
2018-01-25 |
New York University |
Specific murine and humanized monoclonal antibodies detecting pathology associated secondary structure changes in proteins and peptides
|
|
CN117820467A
(zh)
*
|
2016-12-07 |
2024-04-05 |
基因泰克公司 |
抗tau抗体和使用方法
|
|
MA48595A
(fr)
|
2016-12-07 |
2020-03-18 |
Ac Immune Sa |
Anticorps anti-tau et leurs méthodes d'utilisation
|
|
RU2768404C2
(ru)
*
|
2016-12-23 |
2022-03-24 |
Ремд Биотерапьютикс, Инк. |
Иммунотерапия с применением антител, связывающих белок 1 программируемой смерти клеток (pd-1)
|
|
AU2017385274B2
(en)
|
2016-12-26 |
2024-02-22 |
Jcr Pharmaceuticals Co., Ltd. |
Fusion protein including BDNF
|
|
TWI761413B
(zh)
|
2016-12-26 |
2022-04-21 |
日商Ｊｃｒ製藥股份有限公司 |
通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
|
|
US12049493B2
(en)
*
|
2017-01-06 |
2024-07-30 |
Abl Bio Inc. |
Anti-alpha-synuclein antibodies and uses thereof
|
|
CN118184777A
(zh)
*
|
2017-01-30 |
2024-06-14 |
亚力兄制药公司 |
单价抗备解素抗体及抗体片段
|
|
EP3580241A4
(en)
*
|
2017-02-10 |
2021-01-06 |
The Trustees Of The University Of Pennsylvania |
ANTIFACTOR D ANTIBODIES AND USES THEREOF
|
|
US11578137B2
(en)
*
|
2017-03-06 |
2023-02-14 |
The Trustees Of The University Of Pennsylvania |
Anti-C5 antibodies and uses thereof
|
|
BR112019019595A2
(pt)
*
|
2017-03-23 |
2020-04-14 |
Univ Pennsylvania |
anticorpo, métodos para tratar uma doença ou distúrbio mediado pela via do complemento em um indivíduo e para reduzir a atividade de um sistema complemento de um indivíduo, e, célula
|
|
EP3601346A1
(en)
*
|
2017-03-29 |
2020-02-05 |
H. Hoffnabb-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
|
CN110691793A
(zh)
*
|
2017-04-26 |
2020-01-14 |
田边三菱制药株式会社 |
黏结蛋白聚糖-1（cd138）结合剂及其用
|
|
CN110881274B
(zh)
|
2017-05-02 |
2024-11-15 |
普罗塞纳生物科学有限公司 |
识别tau的抗体
|
|
CA3064785A1
(en)
*
|
2017-05-30 |
2018-12-06 |
The University Of British Columbia |
Epitopes in the rna recognition motif 1 (rrm1) of tdp-43 and misfolding-selective antibodies thereto
|
|
EP3431496A1
(en)
*
|
2017-07-19 |
2019-01-23 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Anti- isoasp7 amyloid beta antibodies and uses thereof
|
|
AU2018308088B2
(en)
|
2017-07-25 |
2025-05-29 |
Truebinding, Inc. |
Treating cancer by blocking the interaction of TIM-3 and its ligand
|
|
JP7204235B2
(ja)
*
|
2017-08-02 |
2023-01-16 |
ストレスマーク・バイオサイエンシーズ・インコーポレイテッド |
活性型α－シヌクレインに結合する抗体
|
|
JP7356727B2
(ja)
*
|
2017-10-12 |
2023-10-05 |
慶應義塾 |
アクアポリン３（ａｑｐ３）の細胞外ドメインに特異的に結合する抗ａｑｐ３モノクローナル抗体、及びその使用
|
|
KR20200106495A
(ko)
*
|
2017-11-29 |
2020-09-14 |
보오드 오브 리젠츠, 더 유니버시티 오브 텍사스 시스템 |
암 치료요법을 위한 조성물 및 방법
|
|
AU2018379306A1
(en)
*
|
2017-12-05 |
2020-06-25 |
Mabion Sa |
Combination therapy of multiple sclerosis comprising a CD20 ligand
|
|
WO2019118906A2
(en)
*
|
2017-12-14 |
2019-06-20 |
University Of Florida Research Foundation |
Monoclonal antibodies targeting phf1 and at8 epitopes of human tau protein
|
|
US12071483B1
(en)
|
2017-12-14 |
2024-08-27 |
Abl Bio Inc. |
Bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor and use thereof
|
|
WO2019113711A1
(en)
|
2017-12-14 |
2019-06-20 |
University Of Ottawa |
Exosome packaging and targeted autophagy
|
|
EP3732201A4
(en)
|
2017-12-19 |
2022-04-20 |
Surrozen Operating, Inc. |
WNT SURROGATES AND THEIR USES
|
|
CN111699003B
(zh)
*
|
2017-12-19 |
2024-05-03 |
瑟罗泽恩奥普瑞汀公司 |
抗lrp5/6抗体和使用方法
|
|
JP7490565B2
(ja)
*
|
2017-12-29 |
2024-05-27 |
アレクトル エルエルシー |
抗ｔｍｅｍ１０６ｂ抗体及びその使用方法
|
|
EP3735422A1
(en)
*
|
2018-01-05 |
2020-11-11 |
AC Immune SA |
Misfolded tdp-43 binding molecules
|
|
EP3746478A4
(en)
*
|
2018-01-29 |
2022-01-19 |
The Regents of The University of California |
THERAPIES AND METHODS OF TREATING TLR2-MEDIATED DISEASES AND DISORDERS
|
|
CN111971301B
(zh)
|
2018-01-31 |
2025-01-07 |
艾莱克特有限责任公司 |
抗ms4a4a抗体及其使用方法
|
|
CN112204050B
(zh)
|
2018-01-31 |
2025-03-14 |
艾莱克特有限责任公司 |
抗ms4a6a抗体及其使用方法
|
|
JP7539834B2
(ja)
*
|
2018-02-01 |
2024-08-26 |
メモリアル スローン ケタリング キャンサー センター |
ガレクチン－３に対する抗体及びその使用方法
|
|
WO2019161384A1
(en)
*
|
2018-02-19 |
2019-08-22 |
New York University |
Tau single domain antibodies
|
|
KR20200130324A
(ko)
|
2018-02-23 |
2020-11-18 |
에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨 |
Cd83-결합 키메라 항원 수용체
|
|
CA3093692A1
(en)
|
2018-03-14 |
2019-09-19 |
Boehringer Ingelheim International Gmbh |
Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis
|
|
TWI791794B
(zh)
*
|
2018-03-20 |
2023-02-11 |
瑞士商諾華公司 |
藥物組合
|
|
AU2018418224B2
(en)
|
2018-04-09 |
2025-04-17 |
Oricell Therapeutics Co., Ltd. |
Anti-PD-L1 antibody and use thereof
|
|
BR112020020787A2
(pt)
*
|
2018-04-11 |
2021-02-02 |
Tychan Pte. Ltd. |
métodos e composições para o tratamento de febre amarela
|
|
CN112004558A
(zh)
*
|
2018-04-12 |
2020-11-27 |
米迪亚制药有限责任公司 |
Lgals3bp抗体-药物-偶联物及其用于癌症的治疗的用途
|
|
CA3097999A1
(en)
*
|
2018-04-24 |
2019-10-31 |
Neuracle Science Co., Ltd. |
Use of anti-family with sequence similarity 19, member a5 antibodies for the treatment of neuropathic pain
|
|
KR20210005096A
(ko)
*
|
2018-04-25 |
2021-01-13 |
메디뮨 리미티드 |
인간 항-pd-l1 항체의 제형
|
|
BR112020021855A2
(pt)
|
2018-04-27 |
2021-02-23 |
Biogen Ma Inc. |
anticorpo antirrepetição de dipeptídeo (dpr) (poli-ga) derivado de humanos
|
|
GB201806918D0
(en)
*
|
2018-04-27 |
2018-06-13 |
Enleofen Bio Pte Ltd |
Combination treatment for eye fibrosis
|
|
US11613571B2
(en)
*
|
2018-05-23 |
2023-03-28 |
Glaxosmithkline Intellectual Property Development Limited |
Biopharmaceutical compositions comprising antibody variants
|
|
WO2019225787A1
(ko)
*
|
2018-05-24 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-b7-h3 항체 및 그 용도
|
|
WO2019229296A1
(en)
*
|
2018-05-29 |
2019-12-05 |
Teknologian Tutkimuskeskus Vtt Oy |
Anti-thyroid hormone (t4) recombinant antibody or antigen binding fragment
|
|
EP3802600A1
(en)
*
|
2018-05-31 |
2021-04-14 |
Ichnos Sciences S.A. |
Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders
|
|
CN110577597B
(zh)
*
|
2018-06-11 |
2021-10-22 |
康诺亚生物医药科技（成都）有限公司 |
一种阻断CD47和SIRPα相互作用的抗体
|
|
KR20210031694A
(ko)
*
|
2018-06-14 |
2021-03-22 |
베쓰 이스라엘 디코니스 메디칼 센터 인크 |
엑토뉴클레오티다제 억제 및 항체-매개된 표적 사이토시스를 통한 t-세포 고갈을 예방 또는 역전시키는 조성물 및 방법
|
|
JP7513533B2
(ja)
*
|
2018-07-02 |
2024-07-09 |
アブセントラ，エルエルシー |
リポタンパク質ａの形成を減少させるための組成物及び方法、ならびに大動脈弁硬化症及び大動脈弁狭窄症の治療
|
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
|
PL3820569T3
(pl)
|
2018-07-12 |
2025-07-14 |
Invox Pharma Limited |
Cząsteczki przeciwciał, które wiążą PD-L1 oraz CD137
|
|
GB201811404D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-CD137 Antibodies
|
|
GB201811415D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-Mesothelin Anti bodies
|
|
GB201811450D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Delta Ltd |
Mesothelin and CD137 binding molecules
|
|
BR112021000282A2
(pt)
*
|
2018-07-12 |
2021-04-06 |
F-Star Beta Limited |
Moléculas de anticorpo que se ligam a cd137 e ox40
|
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
|
GB201811403D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Antibody molecules
|
|
CN110713537B
(zh)
*
|
2018-07-13 |
2023-04-21 |
江苏怀瑜药业有限公司 |
一种sema4d抗体及其制备方法和应用
|
|
WO2020024931A1
(en)
*
|
2018-07-31 |
2020-02-06 |
Shen Weiqun |
Anti-il-17a antibodies and use thereof
|
|
WO2020033646A1
(en)
*
|
2018-08-08 |
2020-02-13 |
Orionis Biosciences, Inc. |
SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF
|
|
KR102666754B1
(ko)
*
|
2018-08-21 |
2024-05-17 |
에이비엘바이오 주식회사 |
항-pd-l1/항-lag3 이중 특이 항체 및 이의 용도
|
|
CA3111396A1
(en)
|
2018-09-06 |
2020-03-12 |
The Trustees Of The University Of Pennsylvania |
Humanized anti-c5 antibodies and uses thereof
|
|
CN111253485A
(zh)
*
|
2018-11-30 |
2020-06-09 |
上海开拓者生物医药有限公司 |
抗人tim-3单克隆抗体及其应用
|
|
CN113286825B
(zh)
*
|
2018-11-30 |
2024-06-18 |
爱必乐生物公司 |
抗pd-l1/抗4-1bb双特异性抗体及其用途
|
|
US12269874B2
(en)
*
|
2018-12-03 |
2025-04-08 |
mAbProtein Co., Ltd. |
Antibody that recognizes neoepitope of activated interleukin-18 proteins and application thereof
|
|
US20220040230A1
(en)
*
|
2018-12-11 |
2022-02-10 |
The Regents Of The University Of California |
Compositions and methods for immunotherapies
|
|
TWI734279B
(zh)
*
|
2018-12-14 |
2021-07-21 |
美商美國禮來大藥廠 |
抗α-突觸核蛋白抗體及其用途
|
|
AU2020214796A1
(en)
|
2019-01-30 |
2021-07-29 |
Truebinding, Inc. |
Anti-Gal3 antibodies and uses thereof
|
|
AU2020221324A1
(en)
*
|
2019-02-15 |
2021-09-02 |
University Of Southern California |
Lym-1 and Lym-2 antibody compositions and improved CAR constructs
|
|
EP3924389A4
(en)
*
|
2019-02-15 |
2023-06-14 |
Integral Molecular, Inc. |
CLAUDIN-6 ANTIBODIES AND THEIR USES
|
|
CN113661175A
(zh)
|
2019-02-15 |
2021-11-16 |
整体分子公司 |
包含共同轻链的抗体及其用途
|
|
EP3935083A4
(en)
|
2019-03-03 |
2022-11-30 |
Prothena Biosciences Limited |
Antibodies recognizing tau
|
|
WO2020206232A1
(en)
*
|
2019-04-04 |
2020-10-08 |
Vanderbilt University |
Hiv/hcv cross-reactive antibodies and uses thereof
|
|
EP3958903A4
(en)
*
|
2019-04-24 |
2023-08-02 |
Janssen Biotech, Inc. |
ANTIBODY FORMULATION
|
|
WO2020225736A1
(en)
*
|
2019-05-08 |
2020-11-12 |
Novartis Ag |
Anti-cd40 antibodies for use in treatment of t1dm and insulitis
|
|
TW202110878A
(zh)
*
|
2019-05-16 |
2021-03-16 |
法商賽諾菲公司 |
在神經系統中表現抗原結合蛋白
|
|
WO2020228806A1
(zh)
*
|
2019-05-16 |
2020-11-19 |
齐鲁制药有限公司 |
针对密蛋白18a2的抗体及其应用
|
|
US20220235142A1
(en)
*
|
2019-06-04 |
2022-07-28 |
Shanghai GenBase Biotechnology Co., Ltd. |
Anti-ceacam5 monoclonal antibody, preparation method thereof and use thereof
|
|
WO2020250204A1
(ko)
*
|
2019-06-13 |
2020-12-17 |
프레스티지 바이오파마 피티이. 엘티디. |
신규 cthrc1에 특이적 항체 및 이의 용도
|
|
FR3099160B1
(fr)
*
|
2019-07-23 |
2022-05-06 |
Univ Grenoble Alpes |
Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant
|
|
MY205369A
(en)
*
|
2019-07-26 |
2024-10-17 |
Sinocelltech Ltd |
Humanized anti-il17a antibody and use thereof
|
|
MX2022001260A
(es)
*
|
2019-07-31 |
2022-04-18 |
Alector Llc |
Anticuerpos anti-ms4a4a y metodos de uso de los mismos.
|
|
AU2020334893A1
(en)
*
|
2019-08-16 |
2022-02-24 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
Chimeric antigen receptors for treating myeloid malignancies
|
|
WO2021057930A1
(en)
*
|
2019-09-26 |
2021-04-01 |
Wuxi Biologics (Shanghai) Co., Ltd. |
A novel anti-pd-l1/anti-lag-3 bispecific antibody and uses thereof
|
|
WO2021058718A1
(en)
*
|
2019-09-26 |
2021-04-01 |
Roche Diagnostics Gmbh |
Anti-csf-1r antibody
|
|
EP4041757A4
(en)
*
|
2019-09-26 |
2024-04-17 |
Regents of the University of Minnesota |
VIRAL ANTIGEN BINDING NK ENGAGERS COMPOUNDS AND METHODS OF USE
|
|
AU2020360849A1
(en)
*
|
2019-09-30 |
2022-04-14 |
New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery |
Protein binders to iRhom2 epitopes
|
|
EP4041308A1
(en)
|
2019-10-07 |
2022-08-17 |
University of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
|
AU2020380588A1
(en)
*
|
2019-11-04 |
2022-06-09 |
Medimmune Limited |
Anti IL-33 therapeutic agent FPR treating renal disorders
|
|
JP6761889B1
(ja)
*
|
2019-11-11 |
2020-09-30 |
株式会社Ｇｓｐエンタープライズ |
抗ヒトＣｒｉｐｔｏ−１抗体
|
|
US20220275103A1
(en)
*
|
2019-11-18 |
2022-09-01 |
CentricsBio, Inc. |
Anti-cd300c monoclonal antibody and biomarker thereof for preventing or treating cancer
|
|
WO2021102131A1
(en)
*
|
2019-11-21 |
2021-05-27 |
Brown University |
Bispecific antibodies against chi3l1 and ctla4 with enhanced cytotoxic effects on tumor cells
|
|
WO2021110930A1
(en)
*
|
2019-12-06 |
2021-06-10 |
Universiteit Antwerpen |
Combination immunotherapy of il-15 and cd40 agonist in cancer treatment
|
|
MX2022007688A
(es)
*
|
2019-12-20 |
2022-07-19 |
Amgen Inc |
Constructos de anticuerpo multiespecificos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores solidos.
|
|
WO2021146218A1
(en)
*
|
2020-01-13 |
2021-07-22 |
Truebinding, Inc. |
Anti-gal3 antibodies and methods of use
|
|
JP7449390B2
(ja)
*
|
2020-01-24 |
2024-03-13 |
ファイザー・インク |
抗ｅ－セレクチン抗体、組成物および使用の方法
|
|
EP4093426A1
(en)
|
2020-01-24 |
2022-11-30 |
University of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
|
WO2021158178A1
(en)
*
|
2020-02-07 |
2021-08-12 |
Agency For Science, Technology And Research |
Antigen-binding molecules against alppl2 and/or alpp and uses thereof
|
|
MX2022009476A
(es)
*
|
2020-02-10 |
2022-08-22 |
Regeneron Pharma |
Anticuerpos anti-tmprss2 y fragmentos de union a antigeno.
|
|
WO2021163346A2
(en)
*
|
2020-02-12 |
2021-08-19 |
The Scripps Research Institute |
Long-acting gm-csf and methods of use
|
|
WO2021162394A1
(ko)
*
|
2020-02-14 |
2021-08-19 |
충북대학교 산학협력단 |
B세포 성숙화 항원을 표적으로 하는 키메라 항원 수용체 및 이의 용도
|
|
GB202003632D0
(en)
*
|
2020-03-12 |
2020-04-29 |
Harbour Antibodies Bv |
SARS-Cov-2 (SARS2, COVID-19) antibodies
|
|
US20230192877A1
(en)
*
|
2020-03-30 |
2023-06-22 |
National Institutes Of Biomedical Inovation, Health And Nutriton |
Epitope region-bridging biparatopic antibody and method for producing same
|
|
CR20220552A
(es)
|
2020-04-02 |
2023-01-17 |
Regeneron Pharma |
Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
|
|
KR102485892B1
(ko)
*
|
2020-04-09 |
2023-01-09 |
주식회사 에이프릴바이오 |
고양이 과립구 집락 자극인자 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도
|
|
BR112022021604A2
(pt)
*
|
2020-04-28 |
2022-12-06 |
Sola Biosciences Llc |
Composições e métodos para tratamento de proteinopatias associadas à tdp-43
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
WO2021242776A2
(en)
|
2020-05-26 |
2021-12-02 |
Truebinding, Inc. |
Methods of treating inflammatory diseases by blocking galectin-3
|
|
MX2022014734A
(es)
*
|
2020-05-26 |
2023-03-15 |
Regeneron Pharma |
Metodos de tratamiento del cancer de cuello uterino mediante la administracion del anticuerpo inhibidor de pd-1 cemiplimab.
|
|
CN116323665A
(zh)
*
|
2020-05-29 |
2023-06-23 |
23和我公司 |
抗cd200r1抗体及其使用方法
|
|
KR20230020521A
(ko)
*
|
2020-06-04 |
2023-02-10 |
셀벡스 피티와이 리미티드 |
아고니스트 항-cd40 항체
|
|
US20230341408A1
(en)
*
|
2020-06-08 |
2023-10-26 |
University Of Florida Research Foundation, Inc. |
Materials and methods for the diagnosis and treatment of cancer
|
|
CA3182384A1
(en)
*
|
2020-06-18 |
2021-12-23 |
Jay M. Short |
Conditionally active anti-cd46 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
|
KR20230038706A
(ko)
*
|
2020-07-16 |
2023-03-21 |
난징 레전드 바이오테크 씨오., 엘티디. |
Cd19 결합 분자 및 이의 용도
|
|
US20230257475A1
(en)
*
|
2020-07-16 |
2023-08-17 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific chimeric antigen receptors and uses thereof
|
|
EP4182022A1
(en)
|
2020-07-17 |
2023-05-24 |
Boehringer Ingelheim International GmbH |
Anti-il-36r antibodies for the treatment of neutrophilic dermatoses
|
|
EP4188960A4
(en)
*
|
2020-08-03 |
2024-09-11 |
Janssen Biotech, Inc. |
MATERIALS AND METHODS FOR MULTIDIRECTIONAL BIOTRANSPORTATION IN VIROTHERAPEUTIC PRODUCTS
|
|
WO2022034920A1
(en)
*
|
2020-08-14 |
2022-02-17 |
Chugai Seiyaku Kabushiki Kaisha |
One-armed antigen-binding molecules and uses thereof
|
|
US12129290B2
(en)
*
|
2020-08-18 |
2024-10-29 |
Omeros Corporation |
Monoclonal antibodies, compositions and methods for detecting complement factor D
|
|
EP4199968A1
(en)
*
|
2020-08-20 |
2023-06-28 |
Ambrx, Inc. |
Antibody-tlr agonist conjugates, methods and uses thereof
|
|
TWI818308B
(zh)
*
|
2020-09-03 |
2023-10-11 |
大陸商和鉑醫藥（上海）有限責任公司 |
標靶ｒｏｒ１的抗體或其抗原結合片段及製備方法和應用
|
|
US12448449B2
(en)
*
|
2020-09-11 |
2025-10-21 |
Janssen Biotech, Inc. |
Immune targeting molecules and uses thereof
|
|
US11905332B2
(en)
|
2020-09-18 |
2024-02-20 |
Regeneron Pharmaceuticals, Inc. |
Antigen-binding molecules that bind CD38 and/or CD28, and uses thereof
|
|
KR20230088370A
(ko)
*
|
2020-09-18 |
2023-06-19 |
아이크노스 사이언스 에스. 아. |
Cd47-cd38 이중특이성 항체
|
|
WO2022068141A1
(zh)
*
|
2020-09-29 |
2022-04-07 |
昆明赛诺制药股份有限公司 |
人源化抗-cd22重组免疫毒素及其应用
|
|
WO2022072508A1
(en)
*
|
2020-09-30 |
2022-04-07 |
Dren Bio, Inc. |
Anti-cd94 antibodies and methods of use thereof
|
|
EP4236988A4
(en)
*
|
2020-10-30 |
2024-10-30 |
Rush University Medical Center |
INTRANASAL IMMUNOTHERAPY FOR THE TREATMENT OF ALZHEIMER'S DISEASE
|
|
CN117264060A
(zh)
*
|
2020-11-09 |
2023-12-22 |
江苏中新医药有限公司 |
抗胞外-5’-核苷酸酶的抗体及其在制备肿瘤药物中的应用
|
|
CN114470189B
(zh)
*
|
2020-11-12 |
2024-01-16 |
达石药业(广东)有限公司 |
Ngf抗体在cipn性疼痛中的应用
|
|
JP7326584B2
(ja)
*
|
2020-12-17 |
2023-08-15 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗ｈｌａ－ｇ抗体及びその使用
|
|
AR124410A1
(es)
*
|
2020-12-18 |
2023-03-22 |
Ac Immune Sa |
Administración de anticuerpos
|
|
US12325752B2
(en)
*
|
2020-12-18 |
2025-06-10 |
Regeneron Pharmaceuticals, Inc. |
Immunoglobulin proteins that bind to NPR1 agonists
|
|
CN116635426A
(zh)
*
|
2021-01-08 |
2023-08-22 |
北京韩美药品有限公司 |
特异性结合cd47的抗体及其抗原结合片段
|
|
CA3204552A1
(en)
*
|
2021-01-08 |
2022-07-14 |
Joseph M. LUETTGEN |
Antibodies and antigen binding peptides for factor xia inhibitors and uses thereof
|
|
CA3209006A1
(en)
*
|
2021-03-04 |
2022-09-09 |
Boehringer Ingelheim International Gmbh |
Methods for the treatment of gpp
|
|
JP2024511319A
(ja)
|
2021-03-09 |
2024-03-13 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
|
|
JP2024509274A
(ja)
*
|
2021-03-10 |
2024-02-29 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
|
|
MX2023010917A
(es)
*
|
2021-03-18 |
2023-09-27 |
Medimmune Ltd |
Molecula de union terapeutica que se une a ccr9.
|
|
TW202304988A
(zh)
*
|
2021-03-24 |
2023-02-01 |
美商健生生物科技公司 |
靶向ＣＤ７９ｂ、ＣＤ２０、及ＣＤ３之三特異性抗體
|
|
CN118165109A
(zh)
*
|
2021-03-31 |
2024-06-11 |
美勒斯公司 |
包含新颖pd-1结合域之多特异性结合部分
|
|
US11993654B2
(en)
*
|
2021-03-31 |
2024-05-28 |
Merus N.V. |
PD-1 binding domains
|
|
PE20232050A1
(es)
*
|
2021-04-06 |
2023-12-27 |
Teneobio Inc |
Anticuerpos anti-cd19 y estructuras car-t
|
|
CN115260312B
(zh)
*
|
2021-04-30 |
2025-02-14 |
保诺科技（北京）有限公司 |
结合ox40的抗体或抗原结合片段
|
|
WO2022271884A2
(en)
*
|
2021-06-22 |
2022-12-29 |
Twist Bioscience Corporation |
Methods and compositions relating to covid antibody epitopes
|
|
TWI864408B
(zh)
*
|
2021-06-25 |
2024-12-01 |
日商中外製藥股份有限公司 |
抗ctla-4抗體的用途
|
|
AU2022299846B2
(en)
*
|
2021-06-25 |
2024-08-15 |
Chugai Seiyaku Kabushiki Kaisha |
Anti–ctla-4 antibody
|
|
US12448451B2
(en)
*
|
2021-06-25 |
2025-10-21 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-CTLA-4 antibody and use thereof
|
|
IL310012A
(en)
*
|
2021-07-14 |
2024-03-01 |
Regeneron Pharma |
Antibodies against SARS-COV-2 spike glycoprotein and antigen-binding fragments
|
|
US11542340B1
(en)
*
|
2021-10-29 |
2023-01-03 |
Biodesix, Inc. |
Antibodies targeting pulmonary nodule specific biomarkers and uses thereof
|
|
IL313265A
(en)
|
2021-12-06 |
2024-08-01 |
Regeneron Pharma |
Antagonistic antibodies against NPR1 and methods of using them
|
|
EP4626933A1
(en)
|
2022-11-30 |
2025-10-08 |
Integral Molecular, Inc. |
Antibodies directed to claudin 6, including bispecific formats thereof
|
|
CN120513256A
(zh)
*
|
2023-01-20 |
2025-08-19 |
迈威(美国)生物治疗有限公司 |
抗淀粉样蛋白β原纤丝/低聚物抗体和其用途
|
|
US20240285789A1
(en)
*
|
2023-02-23 |
2024-08-29 |
University Of Utah Research Foundation |
Compositions and Methods for Killing PD-1 Positive Cells
|
|
WO2024194686A2
(en)
|
2023-03-17 |
2024-09-26 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
WO2025257181A1
(en)
*
|
2024-06-11 |
2025-12-18 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies targeting trans-active response dna-binding protein-43 (tdp-43)
|